Arcutis Biotherapeutics Inc. Common Stock (ARQT)
Stock · NASDAQ · Health Care
$28.85as of 10/16/2026
Price chart
Active signals
ARQT Signal Track Record
How signals performed across all stocks →What ARQT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 40 | +0.7% | 53% | September 15, 2026 |
| Bollinger Band Breakout | 25 | +8.2% | 64% | September 17, 2026 |
| Bollinger Band Breakdown | 21 | -3.2% | 43% | August 28, 2026 |
| 200-Day Moving Average TouchActive now | 7 | +21.6% | 57% | September 18, 2026 |
| Any 20-session window (baseline) | +0.6% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ARQT
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a potent and highly selec…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 354
- Website
- arcutis.com/
Fundamentals
- 1-day range
- $28.15$29.31
- Market cap
- $3.31B
- P/E (trailing)
- 128.52
- P/E (forward)
- 21.19
- EPS (trailing)
- $0.21
- Dividend yield
- —
- Beta
- 1.66
- Avg. volume
- 2.30M
How Arcutis Biotherapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Arcutis Biotherapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ARQTArcutis Biotherapeutics Inc. Common Stock$28.82▼ 0.96%Market cap $3.31BP/E 128.52$19.3$31.77
- NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares$19.83▼ 3.83%Market cap $3.23BP/E —$20.91$42.21
- MBXMBX Biosciences Inc. Common Stock$49.61▼ 2.17%Market cap $3.19BP/E —$12.94$72.64
- QUREuniQure N.V. Ordinary Shares$21.78▼ 3.29%Market cap $3.15BP/E —$8.73$71.5
- IDYAIDEAYA Biosciences Inc. Common Stock$32.85▼ 2.95%Market cap $3.50BP/E —$26.44$42.68
- ALMSAlumis Inc. Common Stock$6.12▼ 3.01%Market cap $3.54BP/E —$4.37$31.35
- RCUSArcus Biosciences Inc. Common Stock$22.12▼ 3.07%Market cap $3.56BP/E —$15.38$31.74
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics Inc. Common Stock | $3.31B | 128.52 | $28.82 | ▼ 0.96% | $19.3$31.77 |
| NAMS NewAmsterdam Pharma Company N.V. Ordinary Shares | $3.23B | — | $19.83 | ▼ 3.83% | $20.91$42.21 |
| MBX MBX Biosciences Inc. Common Stock | $3.19B | — | $49.61 | ▼ 2.17% | $12.94$72.64 |
| QURE uniQure N.V. Ordinary Shares | $3.15B | — | $21.78 | ▼ 3.29% | $8.73$71.5 |
| IDYA IDEAYA Biosciences Inc. Common Stock | $3.50B | — | $32.85 | ▼ 2.95% | $26.44$42.68 |
| ALMS Alumis Inc. Common Stock | $3.54B | — | $6.12 | ▼ 3.01% | $4.37$31.35 |
| RCUS Arcus Biosciences Inc. Common Stock | $3.56B | — | $22.12 | ▼ 3.07% | $15.38$31.74 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why Is Arcutis Biotherapeutics Stock Surging Thursday?benzinga · 10/15/2026
- Arcutis Biotherapeutics (ARQT) Showcased Fresh ZORYVE Data, Is It Still 28% Below Fair Value?Yahoo · 10/10/2026
- Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall ClinicalYahoo · 10/9/2026
- Arcutis Presents ZORYVE Data At EADV CongressBenzinga · 10/9/2026
- Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty AwardYahoo · 10/6/2026
- Arcutis Biotherapeutics: An Emerging GARP StockSeekingAlpha · 10/6/2026
- Arcutis: Every Beat Gets Absorbed By A Shrinking Multiple (Rating Downgrade)SeekingAlpha · 10/6/2026
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 10/2/2026
- Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa StudyYahoo · 10/1/2026
Insider Activity
Insider Actions →- Masaru Matsuda · September 16, 2026 · Sale3.7K @ $25
- Howard G. Welgus · September 15, 2026 · Option Exercise2.3K @ $8.63
- Howard G. Welgus · September 15, 2026 · Option Exercise1.0K @ $7.51
- Howard G. Welgus · September 15, 2026 · Option Exercise822 @ $6.52
- Howard G. Welgus · September 15, 2026 · Sale4.7K @ $24.18
- Masaru Matsuda · September 8, 2026 · Sale10.0K @ $25.03
- Terrie Curran · August 27, 2026 · Option Exercise27.1K @ $8.63
- Terrie Curran · August 27, 2026 · Option Exercise11.1K @ $7.51
- Terrie Curran · August 27, 2026 · Sale27.1K @ $25.03
- Terrie Curran · August 27, 2026 · Sale11.1K @ $25.03
- Terrie Curran · August 20, 2026 · Option Exercise1.1K @ $7.51
- Terrie Curran · August 20, 2026 · Sale1.1K @ $26.04
- Patrick Burnett · August 19, 2026 · Sale1.7K @ $27
- Howard G. Welgus · August 17, 2026 · Option Exercise2.3K @ $8.63
- Howard G. Welgus · August 17, 2026 · Option Exercise1.0K @ $7.51
Institutional Ownership
March 31, 2026
- Total shares held
- 129.13M
- Total value held
- $3.00B
- Institutional holders
- 257
- Unknown12.33M
- Unknown9.87M
- Unknown9.20M
- Unknown8.27M
- Unknown6.30M
- Unknown5.67M
- Unknown4.98M
- Unknown4.87M
- Unknown4.30M
- Unknown4.22M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade
Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.